Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

Endogenously expressed TSH receptors (TSHRs) on orbital fibroblasts of patients with Graves ophthalmopathy (GO) use crosstalk with IGF1 receptors (IGF1R) to synergistically stimulate secretion of hyaluronan (HA), a major component of GO pathology. We previously showed crosstalk occurred upstream of mitogen-activated protein kinase (ERK) phosphorylation. Because other G protein-coupled receptors engage arrestin-β-1 (ARRB1) and ERK, we tested whether ARRB1 was a necessary component of TSHR/IGF1R crosstalk. HA secretion was stimulated by the TSHR-stimulating monoclonal antibodies M22 and KSAb1, or immunoglobulins from patients with GO (GO-Igs). Treatment with M22, as previously shown, resulted in biphasic dose-response stimulation of HA secretion. The high-potency phase was IGF1R dependent, and the low-potency phase was partly IGF1R independent. KSAb1 produced a monophasic dose-response stimulation of HA secretion, whose potency was lowered >20-fold after IGF1R knockdown. ARRB1 knockdown abolished M22's high-potency phase and lowered KSAb1's potency and efficacy. ARRB1 knockdown inhibited GO-Ig stimulation of HA secretion and of ERK phosphorylation. Last, ARRB1 was shown to be necessary for TSHR/IGF1R proximity. In contrast, ARRB2 knockdowns did not show these effects. Thus, TSHR must neighbor IGF1R for crosstalk in GO fibroblasts to occur, and this depends on ARRB1 acting as a scaffold. Similar scaffolding of TSHR and IGF1R by ARRB1 was found in human osteoblast-like cells and human thyrocytes. These findings support a model of TSHR/IGF1R crosstalk that may be a general mechanism for G-protein-coupled receptor/receptor tyrosine kinase crosstalk dependent on ARRB1.

[1]  Alex R. B. Thomsen,et al.  Therapeutic Targeting of Endosomal G-Protein-Coupled Receptors. , 2018, Trends in pharmacological sciences.

[2]  J. Benovic,et al.  Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. , 2018, Trends in biochemical sciences.

[3]  B. Marcus-Samuels,et al.  Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors. , 2018, Thyroid : official journal of the American Thyroid Association.

[4]  G. Kahaly,et al.  TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types , 2017, Endocrinology.

[5]  N. Suleymanova,et al.  Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation , 2017, Oncotarget.

[6]  Y. Peterson,et al.  The Diverse Roles of Arrestin Scaffolds in G Protein–Coupled Receptor Signaling , 2017, Pharmacological Reviews.

[7]  G. Calin,et al.  Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes , 2017, Oncogene.

[8]  Terry J. Smith,et al.  Teprotumumab for Thyroid‐Associated Ophthalmopathy , 2017, The New England journal of medicine.

[9]  C. KriegerChristine,et al.  TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis. , 2017 .

[10]  R. Place,et al.  Inhibiting thyrotropin/insulin‐like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro , 2017, British journal of pharmacology.

[11]  A. Zelmer,et al.  Visualization of Protein-protein Interaction in Nuclear and Cytoplasmic Fractions by Co-immunoprecipitation and In Situ Proximity Ligation Assay. , 2017, Journal of visualized experiments : JoVE.

[12]  NeumannSusanne,et al.  Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium–Iodide Symporter Expression in Primary Cultures of Human Thyrocytes , 2016 .

[13]  R. Place,et al.  TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. , 2016, The Journal of clinical endocrinology and metabolism.

[14]  W. Wiersinga,et al.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy , 2016, European Thyroid Journal.

[15]  R. Bahn Current Insights into the Pathogenesis of Graves’ Ophthalmopathy , 2015, Hormone and Metabolic Research.

[16]  R. Place,et al.  Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins. , 2015, The Journal of clinical endocrinology and metabolism.

[17]  M. Gershengorn,et al.  β‐Arrestin‐1 mediates thyrotropin‐enhanced osteoblast differentiation , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  A. Tee,et al.  Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. , 2014, The Journal of clinical endocrinology and metabolism.

[19]  L. Girnita,et al.  β-Arrestin–biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor–targeting antibodies in Ewing’s sarcoma , 2012, Proceedings of the National Academy of Sciences.

[20]  Seema Kumar,et al.  A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  S. Pyne,et al.  Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow? , 2011, Trends in pharmacological sciences.

[22]  E. Rozengurt,et al.  Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer , 2010, Clinical Cancer Research.

[23]  Aaron S. Gajadhar,et al.  A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases. , 2010, BioTechniques.

[24]  Terry J. Smith,et al.  Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves’ Disease1 , 2008, The Journal of Immunology.

[25]  P. Marin,et al.  GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. , 2007, Trends in pharmacological sciences.

[26]  Z. Goldsmith,et al.  G Protein regulation of MAPK networks , 2007, Oncogene.

[27]  D. Morrison,et al.  Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.

[28]  R. Paschke,et al.  The Human Thyrotropin Receptor Is Predominantly Internalized by β-Arrestin 2 , 2006 .

[29]  Terry J. Smith,et al.  Monoclonal Pathogenic Antibodies to the Thyroid-Stimulating Hormone Receptor in Graves’ Disease with Potent Thyroid-Stimulating Activity but Differential Blocking Activity Activate Multiple Signaling Pathways1 , 2006, The Journal of Immunology.

[30]  K. Siddle,et al.  Grb10 and Grb14: enigmatic regulators of insulin action--and more? , 2005, The Biochemical journal.

[31]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[32]  Terry J. Smith,et al.  Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. , 2004, The Journal of clinical endocrinology and metabolism.

[33]  T. Kohout,et al.  β-Arrestin1 Mediates Insulin-like Growth Factor 1 (IGF-1) Activation of Phosphatidylinositol 3-Kinase (PI3K) and Anti-apoptosis* , 2003, Journal of Biological Chemistry.

[34]  B. Calabretta,et al.  Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.

[35]  R. Lefkowitz,et al.  β-Arrestins Regulate Mitogenic Signaling and Clathrin-mediated Endocytosis of the Insulin-like Growth Factor I Receptor* , 1998, The Journal of Biological Chemistry.

[36]  B. Marcus-Samuels,et al.  TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis. , 2017, Thyroid : official journal of the American Thyroid Association.

[37]  W. Dik,et al.  Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy. , 2016, Experimental eye research.

[38]  Å. Wallén-Mackenzie,et al.  In Situ Proximity Ligation Assay (PLA). , 2015, Methods in molecular biology.

[39]  R. Bahn Graves' ophthalmopathy. , 2010, The New England journal of medicine.